collection
MENU ▼
Read by QxMD icon Read
search

Tolvaptan, Kidney and Hyponatremia

shared collection
27 papers 25 to 100 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
https://www.readbyqxmd.com/read/28652798/combined-aquaretic-and-diuretic-therapy-in-acute-heart-failure
#1
Michael Goyfman, Paul Zamudio, Kristine Jang, Jennifer Chee, Catherine Miranda, Javed Butler, Nand K Wadhwa
INTRODUCTION: Acute heart failure (AHF) is a leading cause of hospitalization and readmission in the US. The present study evaluated maximum diuresis while minimizing electrolyte imbalances, hemodynamic instability, and kidney dysfunction, to achieve a euvolemic state safely in a shorter period of time. METHODS AND RESULTS: A protocol of combined therapy with furosemide, metolazone, and spironolactone, with or without tolvaptan and acetazolamide, was used in 17 hospitalized patients with AHF...
2017: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/25997504/safety-of-add-on-tolvaptan-in-patients-with-furosemide-resistant-congestive-heart-failure-complicated-by-advanced-chronic-kidney-disease-a-sub-analysis-of-a-pharmacokinetics-pharmacodynamics-study
#2
Naoto Tominaga, Keisuke Kida, Naoki Matsumoto, Yoshihiro J Akashi, Fumihiko Miyake, Kenjiro Kimura, Yugo Shibagaki
BACKGROUND: Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances. Coadministration of tolvaptan, a selective vasopressin V2 receptor antagonist, can ameliorate such adverse events by reducing the required dose of loop diuretics; however, the safety of tolvaptan in patients with reduced renal function is not known. As a result, we conducted an exploratory clinical trial of tolvaptan in 22 patients with CHF and advanced chronic kidney disease (CKD)...
July 2015: Clinical Nephrology
https://www.readbyqxmd.com/read/30454744/syndrome-of-inappropriate-antidiuresis
#3
REVIEW
Michael L Moritz
The syndrome of inappropriate antidiuresis (SIAD) is a common cause of hyponatremia in hospitalized children. SIAD refers to euvolemic hyponatremia due to nonphysiologic stimuli for arginine vasopressin production in the absence of renal or endocrine dysfunction. SIAD can be broadly classified as a result of tumors, pulmonary or central nervous system disorders, medications, or other causes such as infection, inflammation, and the postoperative state. The presence of hypouricemia with an elevated fractional excretion of urate can aid in the diagnosis...
February 2019: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/30449775/tolvaptan-efficiently-reduces-intracellular-fluid-working-toward-a-potential-treatment-option-for-cellular-edema
#4
Hiroaki Kawabata, Hirotsugu Iwatani, Yuko Yamamichi, Keiko Shirahase, Naoko Nagai, Yoshitaka Isaka
Objective Tolvaptan is a class of diuretics that reduce body water through aquaresis. One of the most prominent characteristics of these agents is that worsening of the renal function is less likely to occur. We investigated the underlying mechanism concerning the change in the intracellular fluid (ICF) when the body fluid is reduced. Methods In this retrospective observational study, five overhydrated CKD patients with edema or pleural effusion treated with tolvaptan were assessed by the bioelectrical impedance method twice: once before and once after tolvaptan therapy...
November 19, 2018: Internal Medicine
https://www.readbyqxmd.com/read/30369583/effects-of-tolvaptan-on-volume-overload-in-patients-with-heart-failure
#5
Koichiro Kinugawa, Naoki Sato, Takayuki Inomata
The present meta-analysis aimed to evaluate effects of tolvaptan on fluid retention in patients with heart failure who were non-responsive to conventional treatment and to assess differences between effects of low (≤ 15 mg/day) and high (> 15 mg/day) tolvaptan doses.Randomized controlled trials comparing add-on tolvaptan therapy and placebo or therapy with other diuretics in patients with heart failure were identified through a database search. The primary outcomes were changes in body weight and urine volume, and the secondary outcomes were changes in serum sodium and creatinine levels...
October 25, 2018: International Heart Journal
https://www.readbyqxmd.com/read/30147354/effects-of-tolvaptan-on-renal-function-in-chronic-kidney-disease-patients-with-volume-overload
#6
Shunji Suzuki, Norio Hanafusa, Kenji Kubota, Ken Tsuchiya, Kosaku Nitta
Background: Fluid overload in chronic kidney disease (CKD) is generally controlled by diuretics, with potentially harmful effects on renal function. The efficacy of tolvaptan, a vasopressin V2-receptor antagonist and aquaretic, has not been evaluated for fluid control in CKD with reduced renal function. Methods: Each patient from a group of 24 CKD patients on tolvaptan 15 mg/d plus conventional diuretics (T group) was matched by age and sex with a patient from a group of 24 CKD patients on conventional nonaquaretic diuretics alone not associated to tolvaptan other than tolvaptan (C group)...
2018: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/30045645/economic-impact-of-tolvaptan-treatment-vs-fluid-restriction-based-on-real-world-data-among-hospitalized-patients-with-heart-failure-and-hyponatremia
#7
COMPARATIVE STUDY
Joseph F Dasta, Shirin Sundar, Sandra Chase, Melissa Lingohr-Smith, Jay Lin
OBJECTIVES: To estimate the cost difference associated with tolvaptan treatment vs. fluid restriction (FR) among hospitalized patients with heart failure (HF) and hyponatremia (HN) based on a real-world registry of HN patients. METHODS: An Excel-based economic model was developed to evaluate the cost impact of tolvaptan treatment vs. FR. Model input for hospital length of stay (LOS) was based on published data from the Hyponatremia Registry (HNR). Based on HNR data, tolvaptan-treated patients had a 2-day (median) shorter LOS compared to FR...
October 2018: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/30026287/long-term-administration-of-tolvaptan-in-autosomal-dominant-polycystic-kidney-disease
#8
Marie E Edwards, Fouad T Chebib, Maria V Irazabal, Troy G Ofstie, Lisa A Bungum, Andrew J Metzger, Sarah R Senum, Marie C Hogan, Ziad M El-Zoghby, Timothy L Kline, Peter C Harris, Frank S Czerwiec, Vicente E Torres
BACKGROUND AND OBJECTIVES: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy...
August 7, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/29998996/clinical-effect-of-long-term-administration-of-tolvaptan-in-patients-with-heart-failure-and-chronic-kidney-disease
#9
Yohei Ono, Hiroto Takamatsu, Masahiro Inoue, Yukio Mabuchi, Tetsuya Ueda, Tadashi Suzuki, Masahiko Kurabayashi
The effectiveness of long-term administration of tolvaptan in heart failure (HF) patients with chronic kidney disease (CKD) has not been fully studied. Hence, in this study, we investigated the effects of chronic administration of tolvaptan on patients with HF and CKD. We consecutively enrolled 31 patients with acute HF syndrome (AHFS) who were administrated tolvaptan as a long-term medication (TLV group). All patients had a history of prior HF admission and CKD. We also consecutively enrolled 27 patients with AHFS, a prior history of HF and CKD (conventional group)...
2018: Drug Discoveries & Therapeutics
https://www.readbyqxmd.com/read/29934667/comparison-of-the-effects-of-tolvaptan-and-furosemide-on-renal-water-and-sodium-excretion-in-patients-with-heart-failure-and-advanced-chronic-kidney-disease-a-subanalysis-of-the-k-star-study
#10
Naoto Tominaga, Keisuke Kida, Takayuki Inomata, Naoki Sato, Tohru Izumi, Yoshihiro J Akashi, Yugo Shibagaki
BACKGROUND: Tolvaptan (TLV) is known to increase electrolyte-free water clearance. However, TLV actions on renal electrolytes including urine sodium (uNa) excretion and its consequences are less well understood. This subanalysis investigated the effect of add-on TLV compared to increased furosemide (FUR) on both electrolyte-free water and electrolyte clearance in patients with congestive heart failure (CHF) complicated by advanced chronic kidney disease (CKD). METHODS: The Kanagawa Aquaresis Investigators Trial of TLV on HF Patients with Renal Impairment (K-STAR) was a multicenter, open-labeled, randomized, and controlled prospective clinical study...
June 22, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/26239456/hyponatremia-associated-with-heart-failure-pathological-role-of-vasopressin-dependent-impaired-water-excretion
#11
REVIEW
San-E Ishikawa
An exaggerated increase in circulatory blood volume is linked to congestive heart failure. Despite this increase, reduction of the "effective circulatory blood volume" in congestive heart failure is associated with decreased cardiac output, and can weaken the sensitivity of baroreceptors. Thereafter, tonic inhibition of the baroreceptor-mediated afferent pathway of vagal nerves is removed, providing an increase in non-osmotic release of arginine vasopressin (AVP). In the renal collecting duct, the aquaporin-2 (AQP2) water channel is regulated by sustained elevation of AVP release, and this leads to augmented hydroosmotic action of AVP, that results in exaggerated water retention and dilutional hyponatremia...
2015: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29801549/tolvaptan-for-the-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-is-the-dose-too-high
#12
EDITORIAL
Richard H Sterns
No abstract text is available yet for this article.
June 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29655243/tolvaptan-alleviates-excessive-fluid-retention-of-nephrotic-diabetic-renal-failure-unresponsive-to-furosemide
#13
Tesshu Takada, Tsuguto Masaki, Ayako Hoshiyama, Takuya Toki, Yuji Kamata, Masayoshi Shichiri
Patients with diabetic nephropathy develop nephrotic syndrome, and may show limited response to conventional therapy. They often require earlier initiation of renal replacement therapy because they become refractory to diuretics, and experience excessive fluid retention. We aimed to investigate the efficacy of tolvaptan, an oral arginine vasopressin type 2 receptor antagonist, in a case series of 14 severe diabetic renal failure patients who were severely refractory to maximal doses of furosemide and had excessive fluid retention despite preserved cardiac function and residual renal function...
April 14, 2018: Nephrology
https://www.readbyqxmd.com/read/29154417/impact-of-chronic-kidney-disease-on-the-diuretic-response-of-tolvaptan-in-acute-decompensated-heart-failure
#14
Shuntaro Ikeda, Kiyotaka Ohshima, Shigehiro Miyazaki, Hisaki Kadota, Hideaki Shimizu, Akiyoshi Ogimoto, Mareomi Hamada
AIM: This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF). METHODS AND RESULTS: Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days to those patients in whom fluid retention was observed even after standard treatment...
November 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29629516/safety-and-efficacy-of-tolvaptan-in-korean-patients-with-hyponatremia-caused-by-the-syndrome-of-inappropriate-antidiuretic-hormone
#15
Sang Woong Han, Joo Hark Yi, Kyung Pyo Kang, Ha Yeon Kim, Soo Wan Kim, Hoon Young Choi, Sung Kyu Ha, Gheun Ho Kim, Yang Wook Kim, Kyung Hwan Jeong, Sug Kyun Shin, Ho Jung Kim
BACKGROUND: The aim of this multicenter study was to evaluate the safety and efficacy of tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). METHODS: Of 51 enrolled patients with SIADH, 39 patients (16 female patients, aged 70.8 ± 11.3 years) were included in an intention to treat analysis. All patients received 15 mg/day as the initial dose, and the dose was then increased up to 60 mg/day (as needed) until day 4...
April 9, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29602756/tolvaptan-for-heart-failure-in-chronic-kidney-disease-patients-a-systematic-review-and-meta-analysis
#16
REVIEW
Jonathan Sen, Erin Chung, Darryl McGill
BACKGROUND: Heart failure (HF) is frequently associated with renal impairment. Tolvaptan is reported to be effective in treating congestion in HF without significant electrolyte loss compared to conventional diuretics. However, the safety and efficacy of its use in patients with chronic kidney disease (CKD) is uncertain. This systematic review and meta-analysis evaluated the efficacy and safety outcomes of tolvaptan for HF management in patients with CKD, with a focus at a physiologic basis related to safety...
August 2018: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28725324/cardiorenal-syndrome-role-of-arginine-vasopressin-and-vaptans-in-heart-failure
#17
REVIEW
Poornima Vinod, Vinod Krishnappa, Abigail M Chauvin, Anshika Khare, Rupesh Raina
Heart and kidney failure continued to be of increasing prevalence in today's society, and their comorbidity has synergistic effect on the morbidity and mortality of patients. Cardiorenal syndrome (CRS) is a complex disease with multifactorial pathophysiology. Better understanding of this pathophysiological network is crucial for the successful intervention to prevent advancement of the disease process. One of the major factors in this process is neurohormonal activation, predominantly involving renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP)...
June 2017: Cardiology Research
https://www.readbyqxmd.com/read/28432473/vasopressin-and-vasopressin-antagonists-in-heart-failure
#18
REVIEW
Julie K Vishram-Nielsen, Finn Gustafsson
Despite the introduction of multiple new pharmacological agents over the past three decades in the field of heart failure (HF), overall prognosis remains poor. Hyponatremia is prevalent in HF patients and has been suggested as a contributor to poor response to standard therapy. Elevated levels of arginine vasopressin (AVP), a peptide hormone produced in the hypothalamus, play a role in development of hyponatremia, and AVP and its surrogate, copeptin, are related to changes in osmolality, hemodynamics, neuro-hormones as well as in overall outcome in HF patients...
2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/26990144/diuretic-usage-for-protection-against-end-organ-damage-in-liver-cirrhosis-and-heart-failure
#19
REVIEW
Takefumi Mori, Yusuke Ohsaki, Ikuko Oba-Yabana, Sadayoshi Ito
Volume overload is common in liver cirrhosis, heart failure, and chronic kidney disease, being an independent risk factor for mortality. Loop diuretics have been widely used for treating volume overload in these patients. However, there is a tendency to increase the dose of loop diuretics partly because of diuresis resistance. Neurohormonal factors are also enhanced in these patients, which play a role in volume overload and organ ischemia. Loop diuretics cannot improve neurohormonal factors and could result in end-organ damage...
January 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/26584969/diagnosing-and-treating-the-syndrome-of-inappropriate-antidiuretic-hormone-secretion
#20
Joseph G Verbalis, Arthur Greenberg, Volker Burst, Jean-Philippe Haymann, Gudmundur Johannsson, Alessandro Peri, Esteban Poch, Joseph A Chiodo, Jiten Dave
BACKGROUND: The syndrome of inappropriate antidiuretic hormone secretion is the most common cause of hyponatremia in clinical practice, but current management of hyponatremia and outcomes in patients with syndrome of inappropriate antidiuretic hormone secretion are not well understood. The objective of the Hyponatremia Registry was to assess the current state of management of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion in diverse hospital settings, specifically which diagnostic and treatment modalities are currently used and how rapidly and reliably they result in an increase in serum sodium concentration ([Na(+)])...
May 2016: American Journal of Medicine
label_collection
label_collection
1617
1
2
2015-11-23 16:06:22
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"